Identification of angiogenesis/metastases genes predicting chemoradiotherapy response in patients with laryngopharyngeal carcinoma.

PURPOSE To identify genes related to angiogenesis/metastasis that predict locoregional failure in patients with laryngopharyngeal cancer (LPC) undergoing chemoradiotherapy (CRT) treatment. METHODS Tumor tissue was collected and snap-frozen from 35 sequential patients with histologically confirmed LPC being treated with CRT. Gene expression analysis was performed using a novel cDNA array consisting of 277 genes functionally associated with angiogenesis (n = 152) and/or metastasis (n = 125). Locoregional response was correlated to the gene expression profiles to identify genes associated with outcome. These genes were internally validated by real-time reverse transcriptase polymerase chain reaction (RT-PCR) and validated externally by immunohistochemistry analysis on an independent set of patients. RESULTS Locoregional failure occurred in nine of 35 patients. Seventeen genes from the cDNA microarray correlated with locoregional failure (two-sample t test, P < .05). Seven genes were chosen for additional analysis based on the availability of antibodies for immunohistochemistry. Of these seven genes, real-time RT-PCR validated four genes: MDM2, VCAM-1, erbB2, and H-ras (Wilcoxon rank sum test, P = .008, .02, .04, and .04, respectively). External validation by immunohistochemistry confirmed MDM2 and erbB2 as being predictive of locoregional response. Controlling for stage of disease, positivity for MDM2 or erbB2 was an independent negative predictor of locoregional disease-free survival. CONCLUSION Genomic screening by cDNA microarray and validation internally by real-time RT-PCR and externally by immunohistochemistry have identified two genes (MDM2 and erbB2) as predictors of locoregional failure in LPC patients treated with CRT. The role of these genes in treatment selection and the functional basis for their activity in CRT response merit additional consideration.

[1]  J. Shah,et al.  Postoperative complications of salvage total laryngectomy , 2005, Cancer.

[2]  G. Tortora,et al.  Chemosensitization by antisense oligonucleotides targeting MDM2. , 2005, Current cancer drug targets.

[3]  I. Nishimoto,et al.  Expression of fatty acid synthase, ErbB2 and Ki-67 in head and neck squamous cell carcinoma. A clinicopathological study. , 2004, Oral oncology.

[4]  Yusuke Nakamura,et al.  Prediction of response to neoadjuvant chemotherapy for osteosarcoma by gene-expression profiles. , 2004, International journal of oncology.

[5]  Andrew J. Wilson,et al.  Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin. , 2003, Cancer research.

[6]  Hui Wang,et al.  Chemosensitization and Radiosensitization of Human Cancer by Antisense Anti‐MDM2 Oligonucleotides , 2003, Annals of the New York Academy of Sciences.

[7]  Y. Kajiyama,et al.  c-erbB-2 oncoprotein expression related to chemoradioresistance in esophageal squamous cell carcinoma. , 2003, International journal of radiation oncology, biology, physics.

[8]  T. Carey,et al.  P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines , 2003, Head & neck.

[9]  Yusuke Nakamura,et al.  Expression profiles of non-small cell lung cancers on cDNA microarrays: Identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs , 2003, Oncogene.

[10]  R. Weber,et al.  Outcome of salvage total laryngectomy following organ preservation therapy: the Radiation Therapy Oncology Group trial 91-11. , 2003, Archives of otolaryngology--head & neck surgery.

[11]  J. Forteza,et al.  Predictive Value of P53, BCL-2, and BAX in Advanced Head and Neck Carcinoma , 2002, American journal of clinical oncology.

[12]  S. Tsujitani,et al.  Expression of the Murine Double Minute Gene 2 Oncoprotein in Esophageal Squamous Cell Carcinoma as a Novel Marker for Lack of Response to Chemoradiotreatment , 2002, American journal of clinical oncology.

[13]  Yusuke Nakamura,et al.  Prediction of chemosensitivity for patients with acute myeloid leukemia, according to expression levels of 28 genes selected by genome-wide complementary DNA microarray analysis. , 2002, Molecular cancer therapeutics.

[14]  A. Harris,et al.  Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. , 2002, International journal of radiation oncology, biology, physics.

[15]  J. Shah,et al.  Alteration of p53 pathway in squamous cell carcinoma of the head and neck: impact on treatment outcome in patients treated with larynx preservation intent. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. Wicha,et al.  Expression of Bcl‐2 Family Proteins in Advanced Laryngeal Squamous Cell Carcinoma: Correlation With Response to Chemotherapy and Organ Preservation , 2002, The Laryngoscope.

[17]  S. Dudoit,et al.  Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. , 2002, Nucleic acids research.

[18]  Benjamin D. Smith,et al.  Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  J. Kurebayashi,et al.  Anti‐HER2‐antibody enhances irradiation‐induced growth inhibition in head and neck carcinoma , 2001, International journal of cancer.

[20]  J. Myles,et al.  P53 and Ki‐67 as Outcome Predictors for Advanced Squamous Cell Cancers of the Head and Neck Treated With Chemoradiotherapy , 2001, The Laryngoscope.

[21]  T Tanaka,et al.  Prediction of sensitivity of esophageal tumors to adjuvant chemotherapy by cDNA microarray analysis of gene-expression profiles. , 2001, Cancer research.

[22]  M. Oh,et al.  Issues in cDNA microarray analysis: quality filtering, channel normalization, models of variations and assessment of gene effects. , 2001, Nucleic acids research.

[23]  Geoffrey Childs,et al.  Molecular classification of head and neck squamous cell carcinoma using cDNA microarrays , 2001, Nature Genetics.

[24]  J. Manola,et al.  Her-2-neu expression and progression toward androgen independence in human prostate cancer. , 2000, Journal of the National Cancer Institute.

[25]  Thomas D. Schmittgen,et al.  Effect of experimental treatment on housekeeping gene expression: validation by real-time, quantitative RT-PCR. , 2000, Journal of biochemical and biophysical methods.

[26]  J. Giralt,et al.  Preoperative induction chemotherapy followed by concurrent chemoradiotherapy in advanced carcinoma of the oral cavity and oropharynx , 2000, Cancer.

[27]  N. Sato,et al.  Enhancement of drug-induced apoptosis by antisense oligodeoxynucleotides targeted against Mdm2 and p21WAF1/CIP1. , 2000, Anticancer research.

[28]  D. Botstein,et al.  A gene expression database for the molecular pharmacology of cancer , 2000, Nature Genetics.

[29]  A. Giatromanolaki,et al.  Angiogenesis, thymidine phosphorylase, and resistance of squamous cell head and neck cancer to cytotoxic and radiation therapy. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  L. Le,et al.  MDM2 oncogene as a target for cancer therapy: An antisense approach. , 1999, International journal of oncology.

[31]  A. Harris,et al.  Angiogenesis vs. response after combined chemoradiotherapy of squamous cell head and neck cancer , 1999, International journal of cancer.

[32]  J. Hendry,et al.  Prognostic significance of c-erb B-2 protein expression in carcinoma of the cervix treated with radiotherapy , 1999, Journal of Cancer Research and Clinical Oncology.

[33]  L. Donehower,et al.  Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[34]  T. B. Morrison,et al.  Quantification of low-copy transcripts by continuous SYBR Green I monitoring during amplification. , 1998, BioTechniques.

[35]  A. C. Johannessen,et al.  Expression of c-erbB proto-oncogene family members in squamous cell carcinoma of the head and neck. , 1997, Anticancer research.

[36]  Anthony C. Davison,et al.  Bootstrap Methods and Their Application , 1998 .

[37]  M. Hung,et al.  Strong correlation between c-erbB-2 overexpression and overall survival of patients with oral squamous cell carcinoma. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  M. Strawderman,et al.  Chemotherapy followed by accelerated fractionated radiation for larynx preservation in patients with advanced laryngeal cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  L. Collette,et al.  Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. , 1996, Journal of the National Cancer Institute.

[40]  L. Penland,et al.  Use of a cDNA microarray to analyse gene expression patterns in human cancer , 1996, Nature Genetics.

[41]  A. El‐Naggar,et al.  HER-2/neu oncogene characterization in head and neck squamous cell carcinoma. , 1995, Archives of otolaryngology--head & neck surgery.

[42]  F. Pezzella,et al.  Predictive and prognostic markers in a series of patients with head and neck squamous cell invasive carcinoma treated with concurrent chemoradiation therapy. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[43]  T. Carey,et al.  Overexpression of p53 Predicts Organ Preservation Using Induction Chemotherapy and Radiation in Patients with Advanced Laryngeal Cancer , 1995, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[44]  E. Strong,et al.  Organ-function preservation in advanced oropharynx cancer: results with induction chemotherapy and radiation. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  R. Tibshirani,et al.  An Introduction to the Bootstrap , 1995 .

[46]  L. Pavelic,et al.  Expression of c-erbB-2 gene in human head and neck carcinoma. , 1992, Anticancer research.

[47]  D. Spandidos,et al.  C-erbB-2 expression in squamous cell carcinoma of the head and neck. , 1992, Anticancer research.

[48]  R. Spiro,et al.  Concomitant chemotherapy-radiation therapy followed by hyperfractionated radiation therapy for advanced unresectable head and neck cancer. , 1991, International journal of radiation oncology, biology, physics.

[49]  W. Hong,et al.  Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. , 1991, The New England journal of medicine.

[50]  D. George,et al.  Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. , 1991, The EMBO journal.

[51]  T. Löning,et al.  Expression of c-erbB2 and c-myc in squamous epithelia and squamous cell carcinomas of the head and neck and the lower female genital tract. , 1990, Journal of Oral Pathology & Medicine.

[52]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[53]  Cori Bargmann,et al.  The neu oncogene encodes an epidermal growth factor receptor-related protein , 1986, Nature.